Figure 6.

In vivo activity of palbociclib and single-dose RT against CH157 meningiomas. Survival (A) and BLI (B) results for mice engrafted with CH157, then assigned to one of the following groups: (i) control; (ii) 10 Gy RT only, administered once; (iii) palbociclib only (100 mg/kg/day for 14 consecutive days); (iv) combination of single high dose RT and 14 days of palbociclib. All intergroup comparisons in (A) produced P < 0.05 except for RT vs RT + palbociclib, which was P = 0.167. N = 14 for control and palbociclib, N = 10 for RT and RT + palbociclib.